Liposome

Aesthetic Management Partners Announces Partnership with Croma-pharma To Distribute Plant-Based Exosome Technology to Europe

Retrieved on: 
Thursday, March 28, 2024

With this partnership, Aesthetic Management Partners continues to expand its footprint and introduce the EXO|E™ product line to providers and their patients.

Key Points: 
  • With this partnership, Aesthetic Management Partners continues to expand its footprint and introduce the EXO|E™ product line to providers and their patients.
  • "I am thrilled to announce our partnership with Croma Pharma, bringing the revolutionary EXO|E product line to aesthetic practitioners across Europe and Switzerland," said Erik Dowell, CEO and Founder of Aesthetic Management Partners.
  • By adding the revolutionary EXO|E™ product line to the portfolio, Croma is now offering the latest trend in the aesthetic field.
  • "We are excited to embark on this collaborative journey with Aesthetic Management Partners", said Andreas Prinz, CEO of Croma Pharma.

VAV Enters LatAM with High-Purity Lipids, Eyes 40% Share in Five Years

Retrieved on: 
Thursday, March 7, 2024

VAV Lipids is headquartered in Mumbai, India and is among the world’s leading manufacturers of phospholipids and lecithins.

Key Points: 
  • VAV Lipids is headquartered in Mumbai, India and is among the world’s leading manufacturers of phospholipids and lecithins.
  • The biopharmaceutical company manufactures plant phospholipids (LECIVA), egg phospholipids (LIPOVA), synthetic phospholipids and neutral lipids, APIs and specialty proteins.
  • VAV Lipids will introduce its entire range of products through the company’s distribution network in Latin America.
  • Arun Kedia, Managing Director of VAV Lipids, said, “Our expansion into Latin America will boost our global presence significantly.

Global Nanomedicine Market Report 2023-2028: United States Emerges as a Key Player

Retrieved on: 
Monday, February 26, 2024

DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Nanomedicine Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Nanomedicine Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The nanomedicine market size is still developing, with ongoing research and development aimed at increasing nanomedicine products' efficacy, safety, and scalability.
  • Due to significant investments made by research facilities, pharmaceutical companies, and the government, the United States has a sizable nanomedicine market revenue share.
  • Key Players in the Nanomedicine Market:
    Abbott Laboratories: Nanomaterials, diagnostics, and medical equipment are the primary areas of focus at Abbott Laboratories.

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference

Retrieved on: 
Wednesday, January 24, 2024

MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.

Key Points: 
  • MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.
  • The data will be presented on January 24, 2024, at 7:30 pm MST during a poster presentation.
  • MiNA’s HbF program is designed to increase transcription of the gamma globin (HBG) gene, enabling patients with beta-hemoglobinopathies to produce enhanced levels of HbF.
  • MiNA anticipates advancing its HbF program, the first program to emerge from its genetic medicine portfolio, into pre-clinical development in 2024.

Do liposomes make food supplements more effective? A chemistry expert explains common myths about these products

Retrieved on: 
Wednesday, September 27, 2023

There has been an explosion in nutritional supplements that promise a

Key Points: 
  • There has been an explosion in nutritional supplements that promise a
    superior product because they contain nanoparticles called liposomes.
  • But there’s a lot of misleading information and outright myths about these being shared online, so it’s important to understand how liposomes work before you spend money on an expensive new food supplement.
  • Liposomes can fuse together to form a similar structure to human cell membranes while retaining a liquid core.

Pharmaceutical vs food supplement liposomes

    • This means food supplement companies are having to work harder to convince people their products can overcome this problem.
    • It may seem logical that if liposomes work well for medicines, they could help your body absorb vitamins and other supplements too.
    • In the food supplement industry, there are a multitude of products on the market that are of poor quality or downright fake.
    • In contrast, the liposomes used in food supplements are often the most basic, delicate type.

Do liposomes enhance oral absorption?

    • There are conflicting reports about whether liposomes enhance gastrointestinal absorption.
    • Food supplement liposomes may enhance absorption by improving the ability of the nutrients they contain to fuse with other substances in your food.
    • The same goes for claims that conventional liposomes are absorbed into your bloodstream and remain intact.

Can liposomes be used with any type of nutrient?

    • Even in pharmaceutical research, where more advanced techniques are used, some drug molecules are difficult to fit inside liposomes.
    • Furthermore, liposomes are not an impervious plastic bag, but more akin to a cotton bag through which water can pass.
    • This means if you take a dose, only 10% of it will consist of the drug molecules encapsulated in liposomes.
    • While it might be possible to see larger liposomes using a quality light microscope, the smaller and more effective liposomes are measured in nanometres.

Advancements in Controlled Release Systems: Sustained Drug Release and Targeted Delivery Revolutionize Patient Care - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 27, 2023

As a result, the market for controlled release drug delivery systems is poised to witness substantial growth in the coming years.

Key Points: 
  • As a result, the market for controlled release drug delivery systems is poised to witness substantial growth in the coming years.
  • Controlled release drug delivery systems have revolutionized drug administration by offering sustained release, targeted delivery, and improved patient compliance.
  • Controlled release drug delivery systems enable targeted drug delivery through various strategies.
  • Controlled release drug delivery systems have significantly improved patient care by providing sustained and targeted drug delivery, optimizing treatment outcomes, and enhancing quality of life.

VESSELON TOWN HALL EVENT PROVIDES A GLIMPSE INTO THE FUTURE OF INTRAVENOUS DRUG DEVELOPMENT

Retrieved on: 
Thursday, September 7, 2023

GREENWICH, Conn., Sept. 7, 2023 /PRNewswire/ -- In a digital town hall discussion held with industry analysts, Vesselon CEO and Co-founder Clay Larsen delivered a glimpse into the future of drug development that could revolutionize the pharmaceutical industry. The event, moderated by Endpoints News, showcased how Vesselon's drug platform can extend patents and rapidly create an endless stream of proprietary drugs. The company's bold strategy could yield multiple billion-dollar drug co-formulations by 2030 and redefine the boundaries of drug patents. Sharing the virtual stage with Larsen were EPISTAT CEO Llew Keltner MD, PhD and iECURE Inc. CEO Joe Truitt,

Key Points: 
  • GREENWICH, Conn., Sept. 7, 2023 /PRNewswire/ -- In a digital town hall discussion held with industry analysts, Vesselon CEO and Co-founder Clay Larsen delivered a glimpse into the future of drug development that could revolutionize the pharmaceutical industry.
  • The event, moderated by Endpoints News, showcased how Vesselon's drug platform can extend patents and rapidly create an endless stream of proprietary drugs.
  • The company's bold strategy could yield multiple billion-dollar drug co-formulations by 2030 and redefine the boundaries of drug patents.
  • For a comprehensive look at Vesselon's town hall event, including additional insights from industry experts and audience Q&A, visit www.Vesselon.com/townhall .

Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection

Retrieved on: 
Tuesday, August 29, 2023

Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine" (the "Study").

Key Points: 
  • Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine" (the "Study").
  • In the study, six dogs with naturally-occurring osteoarthritis, unresponsive to conventional medications, were treated with a single injection of five mg/kg liposomal-CBD (in addition to their routine medications).
  • The subsequent observations spanned six weeks and included measuring CBD plasma concentrations, blood work, collar activity data, and evaluations of well-being and pain.
  • The study underscores the effectiveness and increased bioavailability of LPT-CBD tested as part of a multimodal pain management in dogs with osteoarthritis.

Vesselon Introduces the First On-site Co-formulation Platform that Dramatically Improves How Cells Receive and Act on Drugs

Retrieved on: 
Monday, August 28, 2023

GREENWICH, Conn., Aug. 28, 2023 /PRNewswire/ -- Vesselon Inc. introduced the first on-site co-formulation platform that can enhance cellular uptake and response to therapy, without altering the active drug in any way. Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.

Key Points: 
  • Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.
  • Without changing pharmaceutical manufacturing, CMC, or distribution practices, the platform can protect and differentiate an endless stream of blockbuster drugs.
  • "We encapsulate many different classes of drugs, from small molecules, monoclonal antibodies, nucleic acids to viruses," said Clay Larsen, CEO of Vesselon.
  • "I think the best way to think about our approach is that it changes the ability of tissues to receive and act on the drug.